---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-006599"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2025-01-15T23:59:59+00:00"
generated_at: "2026-05-28T01:19:30.437349+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cytek Biosciences expects FY2024 revenue $200-201M, 4% growth; Q4 rev up 11-13% QoQ

## Summary
- Full-year 2024 revenue expected $200-201M, up 4% from $193M in 2023; ~$1M negative FX impact.
- Q4 2024 revenue $57-58M, 11-13% sequential growth, down 2% to flat YoY; FX reduced Q4 by ~$1.5M.
- CEO cites strong APAC and Rest of World growth, offset by order delays and USD strength.
- Preliminary results unaudited; full earnings and 2025 guidance expected late February 2025.
- Company to present at J.P. Morgan Healthcare Conference on January 16, 2025 in San Francisco.

## SEC filing metadata
- accession: 0001193125-25-006599
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2025-01-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312525006599/0001193125-25-006599-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312525006599/d914343d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-006599
- JSON: https://secwatch.observer/filing/0001193125-25-006599.json
- Plain text: https://secwatch.observer/filing/0001193125-25-006599.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.